<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656262</url>
  </required_header>
  <id_info>
    <org_study_id>IOV-2018-STS-METROPHOLYS</org_study_id>
    <nct_id>NCT04656262</nct_id>
  </id_info>
  <brief_title>Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly Patients</brief_title>
  <acronym>METROPHOLYS</acronym>
  <official_title>The METROPHOLYS Study Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients With Advanced Soft Tissue Sarcomas Randomized, Controlled Open Label Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Oncologico Veneto IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Oncologico Veneto IRCCS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the efficacy, as measured by time to treatment failure, of metronomic&#xD;
      cyclophosphamide with respect to doxorubicin in elderly patients affected by mSTS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase III randomized clinical trial was designed to compare metronomic Cyclophosphamide&#xD;
      with standard Doxorubicin for the first-line treatment of elderly cancer patients with&#xD;
      advanced inoperable or metastatic STS:&#xD;
&#xD;
      i) ARM A (experimental): Metronomic Cyclophosphamide ii) ARM B (control): Doxorubicin up to&#xD;
      six cycles&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment failure</measure>
    <time_frame>From date of randomization until the date of treatment discontinuation due to disease progression, toxicity leading to treatment discontinuation, or death, whichever occurs first, assessed up to 12 months</time_frame>
    <description>Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.&#xD;
Toxicity is assessed according to NCI-CTCAE criteria v. 4.03</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free Survival</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months</time_frame>
    <description>Progressive disease is defined as per RECIST 1.1 criteria based on investigator assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from randomization to the date of death due to any cause or last follow up assessed up to 12 months</time_frame>
    <description>Overall Survival is defined as the time from date of randomization to the date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Toxicity Rate</measure>
    <time_frame>From signing IC until 30 days after last study treatment</time_frame>
    <description>Toxicities will be recorded, classified, graded and managed according to NCI CTCAE v. 4.03.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Soft Tissue Sarcoma Adult</condition>
  <arm_group>
    <arm_group_label>Metronomic cyclophosphamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclophosphamide 50 mg daily per os continuously; Patients will be visited for re-cycling every three weeks. Metronomic cyclophosphamide will be taken in the morning along with a full glass of water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 60 mg/mq i.v. in 10 minutes, day 1; to be repeated every three weeks up to a maximum of 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide is formulated as coated tablets of 50mg for oral administration</description>
    <arm_group_label>Metronomic cyclophosphamide</arm_group_label>
    <other_name>Endoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin is formulated as 60 mg/mq for infusional use (i.v use)</description>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients may be included in the study only if they meet all the following criteria:&#xD;
&#xD;
          1. Histologically proven diagnosis of soft tissue sarcoma.&#xD;
&#xD;
          2. Advanced unresectable or metastatic soft tissue sarcoma not previously treated with&#xD;
             chemotherapy for metastatic disease.&#xD;
&#xD;
          3. At least one measurable lesion according to RECIST1.1 criteria.&#xD;
&#xD;
          4. Availability of a tumor sample (primary and/or metastatic sites).&#xD;
&#xD;
          5. Age ≥ 70 years (70-75 years if UNFIT at G8; &gt;75 independent of G8 score)&#xD;
&#xD;
          6. ECOG PS 0-2.&#xD;
&#xD;
          7. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          8. Neutrophils ≥1.5 x 109/L, Platelets ≥100 x 109/L, Hgb ≥ 9 g/dl.&#xD;
&#xD;
          9. Adequate hepatic function, defined as: Total bilirubin ≤ 1.5 time the upper-normal&#xD;
             limits (ULN) of the normal values, ASAT (SGOT) and/or ALAT (SGPT) ≤ 2.5 x ULN (or &lt;5 x&#xD;
             ULN in case of liver metastases)&#xD;
&#xD;
         10. Alkaline phosphatase ≤ 2.5 x ULN (or &lt;5 x ULN in case of liver metastases).&#xD;
&#xD;
         11. Creatinine clearance ≥ 30 mL/min.&#xD;
&#xD;
         12. Normal cardiac function, with left ventricular ejection fraction (LVEF) ≥50%.&#xD;
&#xD;
         13. Male subjects with female partners of childbearing potential must be willing to use&#xD;
             adequate contraception as approved by the investigator&#xD;
&#xD;
         14. Geriatric assessment by means of G8 screening tool and CRASH score.&#xD;
&#xD;
         15. Will and ability to comply with the protocol.&#xD;
&#xD;
         16. Written informed consent to study participation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients will be excluded from the study for any of the following reasons:&#xD;
&#xD;
               1. Previous treatment for metastatic disease.&#xD;
&#xD;
               2. Previous (neo) adjuvant chemotherapy with anthracyclines.&#xD;
&#xD;
               3. Radiotherapy to any site within 4 weeks before the study.&#xD;
&#xD;
               4. Untreated brain metastases or spinal cord compression or primary brain tumors.&#xD;
&#xD;
               5. Active uncontrolled infections or other clinically relevant concomitant illness&#xD;
                  contraindicating chemotherapy administration.&#xD;
&#xD;
               6. Clinically significant (i.e. active) cardiovascular disease for example&#xD;
                  cerebrovascular accidents (≤6 months), myocardial infarction (≤6 months),&#xD;
                  unstable angina, New York Heart Association (NYHA) grade II or greater congestive&#xD;
                  heart failure (CHF), serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
               7. Treatment with any investigational drug within 30 days prior to enrollment or 2&#xD;
                  investigational agent half-lives (whichever is longer)&#xD;
&#xD;
               8. Other co-existing malignancies or malignancies diagnosed within the last 5 years&#xD;
                  with the exception of localized basal and squamous cell carcinoma or cervical&#xD;
                  cancer in situ.&#xD;
&#xD;
               9. Lack of physical integrity of the upper gastrointestinal tract, malabsorption&#xD;
                  syndrome, or inability to take oral medication.&#xD;
&#xD;
              10. Known hypersensitivity to trial drugs or hypersensitivity to any other component&#xD;
                  of the trial drugs.&#xD;
&#xD;
              11. Any concomitant drugs contraindicated for use with the trial drugs according to&#xD;
                  the product information of the pharmaceutical companies.&#xD;
&#xD;
              12. Sexually active males unwilling to practice contraception during the study and&#xD;
                  until 6 months after the last trial treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonella Brunello</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Oncologico Veneto</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gian Luca De Salvo</last_name>
    <phone>0039-049-8215710</phone>
    <email>gianluca.desalvo@iov.veneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margherita Nannini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Marrari, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli IRCCS</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emanuela Palmerini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l'Oncologia IRCCS</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giovanni Grignani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRST Romagnolo IRCCS</name>
      <address>
        <city>Meldola</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toni Ibrahim, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Stracchiotti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto IRCCS</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Brunello, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Giaccone Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Badalamenti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Misericordia e Dolce</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giacomo GI Baldi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Vincenzi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IFO - Istituto Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Presidio Sanitario Humanitas - Gradenico</name>
      <address>
        <city>Torino</city>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Comandone, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOUI Policlinico Borgo Roma</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Cingarlini, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

